Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Langley, Richard ^{[2
]}

Leonardi, Craig ^{[3
]}

Gordon, Kenneth ^{[4
]}

Luger, Thomas ^{[5
]}

Ohtsuki, Mamitoro ^{[6
]}

Nickoloff, Brian ^{[7
]}

Kerr, Lisa ^{[7
]}

Cameron, Gregory ^{[7
]}

Reich, Kristian ^{[8
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Dalhousie Univ, Halifax, NS, Canada

[3] Cent Dermatol, St Louis, MO USA

[4] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[5] Univ Munster, Munster, Germany

[6] Jichi Med Univ, Shimotsuke, Japan

[7] Eli Lilly & Co, Indianapolis, IN 46285 USA

[8] Dermatologikum Hamburg, Hamburg, Germany

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

3232

引用

页码：AB258 / AB258

页数：1

共 50 条

[11] IMMUNOGENICITY OF THE NOVEL ANTI-IL-17A ANTIBODY, SECUKINUMAB, WITH INTRAVENOUS AND SUBCUTANEOUS DOSING REGIMENS IN HEALTHY SUBJECTS AND PATIENTS
Klein, U.
Liang, E.
Vogel, B.
Kolbinger, F.
Bruin, G.
Lloyd, P.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 630 - 630
[12] Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis
Frieder, Jillian
Kivelevitch, Dario
Menter, Alan
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2018, 9 (01) : 5 - 21
[13] Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
Karle, Anette
Spindeldreher, Sebastian
Kolbinger, Frank
MABS, 2016, 8 (03) : 536 - 550
[14] Response of a CARD14-associated papulosquamous eruption to the anti-IL-17A antibody ixekizumab
Klein, Benjamin
Treudler, Regina
Dumann, Konstantin
Boldt, Andreas
Schumann, Isabell
Simon, Jan Christoph
Kunz, Manfred
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 3 - 3
[15] Secukinumab, a novel anti IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays
Reich, Kristian
Blauvelt, Andrew
Armstrong, April
Fox, Todd
Huang, Jiaqing
Liang, Eric
Karle, Anette
Spindeldreher, Sebastian
Bruin, Gerard
Kolbinger, Frank
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB252 - AB252
[16] Population Pharmacokinetics of Xeligekimab: An Anti-IL-17A Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis
Meng, Qingheng
Wang, Wei
Zhang, Lingxiao
Shi, Haiyang
Liu, Hongxia
Zheng, Qingshan
Xu, Ling
JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 65 (01): : 53 - 65
[17] Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis
Gordon, Kenneth
Leonardi, Craig
Braun, Daniel
Cameron, Gregory
Erickson, Janelle
Lebwohl, Mark
Heffernan, Michael
Banerjee, Subhashis
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB183 - AB183
[18] Challenges of systemic IL-17A quantification in patients treated with secukinumab, an anti-IL-17A antibody
Calonder, C.
Helbaj, R.
Spindeldreher, S.
Lloyd, P.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S22 - S22
[19] Preliminary Investigation and Therapeutic Efficacy Determination of a Novel Anti-IL-17A Antibody, Indikizumab
Patra, Ashok Kumar
Nayak, Shreenath
Moharana, Anandita
Ojha, Purusottam
Das, Sanjeet Kumar
Akhtar, Jabed
Giri, Bishwaranjan
Singh, Sujay
BIOLOGICS-TARGETS & THERAPY, 2024, 18 : 257 - 271
[20] Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years
Reich, K.
Blauvelt, A.
Armstrong, A.
Langley, R. G.
de Vera, A.
Kolbinger, F.
Spindeldreher, S.
Ren, M.
Bruin, G.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (09) : 1733 - 1741

← 1 2 3 4 5 →